HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

30 July 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 524669

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: HESTERBIO

Dear Sir/ Madam:

Subject: Outcome of Board Meeting and submission of unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026

This is with reference to our letter dated 23 July 2026 intimating the date of the Board Meeting for consideration of the standalone and consolidated financial results for the quarter ended 30 June 2026.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026, as recommended by Audit Committee.

We attach herewith:
1. The approved unaudited standalone and consolidated financial results and limited review reports
2. A Press Release issued in this regard

We will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 10:30 a.m. (IST) and concluded at 11:07 a.m. (IST).

You are requested to take the above information on your record.

Sincerely
For Hester Biosciences Limited

Vinod Mali
Digitally signed by Vinod Mali
Date: 2026.07.30 11:10:46 +05'30'

Vinod Mali
Company Secretary & Compliance Officer

Enclosure: As above

HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Audited (Refer Note 5)	Unaudited	Audited
	Income				
1	Revenue from Operations	726.60	937.13	634.90	2,921.36
2	Other Income	16.83	41.79	9.46	76.35
	Total income	**743.43**	**978.92**	**644.36**	**2,997.71**
3	**Expenses**				
	(a) Cost of material consumed	107.92	165.14	86.82	462.23
	(b) Purchases of stock-in-trade	55.16	98.33	89.26	394.38
	(c) Change in inventories of finished goods, traded goods and work in progress	(3.48)	(59.98)	18.73	(36.93)
	(d) Employee benefits expense	131.81	139.99	132.45	531.74
	(e) Finance cost	13.64	40.94	9.05	71.69
	(f) Depreciation and amortisation expense	49.18	36.76	21.64	102.52
	(g) Other expenses	191.68	279.00	183.53	845.22
	Total expenses	**545.91**	**700.18**	**541.48**	**2,370.85**
4	**Profit before exceptional items and tax**	**197.52**	**278.74**	**102.88**	**626.86**
5	**Exceptional items (Refer Note 4)**	**-**	**69.96**	**-**	**69.96**
6	**Profit before tax**	**197.52**	**348.70**	**102.88**	**696.82**
7	**Tax Expense**				
	Current tax	45.57	77.23	18.38	144.64
	Tax Adjustment of earlier years	-	0.01	-	0.02
	Deferred tax	4.84	7.62	6.12	31.16
	Total tax expense	**50.41**	**84.86**	**24.50**	**175.82**
8	**Profit after exceptional item and tax**	**147.11**	**263.84**	**78.38**	**521.00**
9	**Other Comprehensive Income**				
	Items that will not be reclassified to Profit or Loss				
	Remeasurement Loss on Defined Benefit Plans	-	(0.67)	(1.21)	(0.67)
	Income tax impact	-	0.17	0.31	0.17
	Total Other Comprehensive Income	**-**	**(0.50)**	**(0.90)**	**(0.50)**
10	**Total Comprehensive Income for the period / year**	**147.11**	**263.34**	**77.48**	**520.50**
11	Paid-up equity share capital	-	-	-	85.07
12	Other Equity	-	-	-	3,766.75
13	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	17.29	31.01	9.21	61.24

HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

Notes:

1 The standalone financial results of Hester Biosciences Limited (the "Company") have been reviewed by the Audit Committee in its meeting held on 29 July 2026 and approved by the Board of Directors of the Company in its meeting held on 30 July 2026

2 The Statutory Auditors have carried out limited review of these standalone financial results of the Company for the quarter ended 30 June 2026.

3 Following are the details of segment wise revenue, results, segment assets and liabilities:

Particulars	Quarter Ended			Year Ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	Unaudited	Audited (Refer note 5)	Unaudited	Audited
Segment Revenue				
a. Poultry Healthcare	618.16	650.72	416.68	2,061.31
b. Animal Healthcare	108.44	286.41	218.22	860.05
Total Revenue from Operations	**726.60**	**937.13**	**634.90**	**2,921.36**
Segment Results				
a. Poultry Healthcare	245.19	235.18	89.69	581.39
b. Animal Healthcare	(8.47)	102.02	35.25	163.85
Total Segment Results	**236.72**	**337.20**	**124.94**	**745.24**
a. Finance Cost	13.64	40.94	9.05	71.69
b. Other unallocable expenditure (Net)	25.56	(52.44)	13.01	(23.27)
Profit before Tax	**197.52**	**348.70**	**102.88**	**696.82**
Segment Assets				
a. Poultry Healthcare	1,237.97	1,229.93	2,418.32	1,229.93
b. Animal Healthcare	640.71	679.80	558.57	679.80
Unallocated Assets	3,731.66	3,663.73	2,438.87	3,663.73
Total	**5,610.34**	**5,573.46**	**5,415.76**	**5,573.46**
Segment Liabilities				
a. Poultry Healthcare	87.85	156.69	134.02	156.69
b. Animal Healthcare	30.59	100.48	164.87	100.48
Unallocated Liabilities	1,492.99	1,464.47	1,648.52	1,464.47
Total	**1,611.43**	**1,721.64**	**1,947.41**	**1,721.64**

Note: Unallocated assets comprise Property, Plant and Equipment and other assets pertaining to the BSL-3 and Fill Finish facilities capitalised during the previous year. As these facilities are intended to support operations across multiple segments and the associated economic benefits are expected to be derived jointly by both segments, the related assets have not been specifically allocated to any individual segment and are accordingly disclosed as unallocated assets.

4 During the previous year, the Board of Directors of the Company at its meeting dated 11 March 2026, has approved the divestment of 43.81% equity shareholding out of 54.81% in its subsidiary, Texas Lifescience Private Limited ("TLPL") by way of sale of 21,63,377 Equity Shares of INR 10 each at the price of INR 42.34 per share to existing promoter shareholders of TLPL. TLPL has been ceased to be subsidiary of the company from 27 March 2026 onwards.

5 The figures for quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full year ended 31 March 2026 and the unaudited published year-to-date figures upto 31 December 2025, being the date of the end of the third quarter which were subjected to limited review.

For and on behalf of the Board of Directors

Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Kadi, Mehsana
Date: 30 July 2026

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's review report on Quarterly Unaudited Standalone Financial Results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Hester Biosciences Limited** for the quarter ended on June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in accordance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a Report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed or that it contains any material misstatement.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W

CHANDULAL M SHAH & CO
AHMEDABAD
CHARTERED ACCOUNTANTS

I. I. Mans

Irshad I Mansuri
Partner
M. No. 135475
UDIN : 26135475KDTWVP5184

Place: Ahmedabad
Date: July 30,2026

HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Audited (Refer Note 6)	Unaudited	Audited
	Income				
1	Revenue from Operations	772.44	1,001.10	841.05	3,325.99
2	Other Income	16.43	(30.28)	23.16	96.84
	Total income	**788.87**	**970.82**	**864.21**	**3,422.83**
3	**Expenses**				
	(a) Cost of material consumed	137.19	212.97	135.58	706.22
	(b) Purchases of stock-in-trade	56.59	56.54	45.87	157.45
	(c) Change in inventories of finished goods, traded goods and work in progress	(22.99)	(75.01)	43.17	(44.08)
	(d) Employee benefits expense	148.84	163.66	152.82	626.67
	(e) Finance cost	30.80	50.95	18.10	109.34
	(f) Depreciation and amortisation expense	70.44	59.14	41.82	188.81
	(g) Other expenses	225.04	299.62	235.47	1,013.15
	Total expenses	**645.91**	**767.87**	**672.83**	**2,757.56**
4	**Profit before Share of Profit of Joint Venture entity, exceptional items and tax**	**142.96**	**202.95**	**191.38**	**665.27**
5	Share of Profit in Joint Venture entity	20.37	18.57	10.49	63.73
6	**Profit before exceptional items and tax**	**163.33**	**221.52**	**201.87**	**729.00**
7	**Exceptional items** (Refer Note 4 for current quarter and Note 5 for previous quarter)	**853.49**	**29.36**	**-**	**29.36**
8	**Profit before tax**	**1,016.82**	**250.88**	**201.87**	**758.36**
9	**Tax expense**				
	Current tax	45.57	77.70	21.55	151.88
	Tax Adjustment of earlier years	-	(0.46)	-	(0.45)
	Deferred tax	3.93	8.18	7.36	32.09
	Total tax expense	**49.50**	**85.42**	**28.91**	**183.52**
10	**Profit after tax**	**967.32**	**165.46**	**172.96**	**574.84**
11	**Other Comprehensive Income**				
	Items that will not be reclassified to Profit or Loss				
	Remeasurement Loss on Defined Benefit Plans	-	(0.04)	(1.36)	(0.47)
	Income tax impact	-	0.01	0.35	0.12
	Items that will be reclassified to Profit or Loss			-	
	Foreign Currency Translation Reserve	(4.45)	(6.28)	(0.75)	(22.93)
	Income Tax Impact	-	-	-	-
	Total Other Comprehensive Income	**(4.45)**	**(6.31)**	**(1.76)**	**(23.28)**
12	**Total Comprehensive Income for the period/year**	**962.87**	**159.15**	**171.20**	**551.56**
13	**Profit for the period/year attributable to:**				
	(i) Owners of the Company	969.81	159.82	164.42	556.39
	(ii) Non-Controlling Interest	(2.49)	5.64	8.54	18.45
14	**Other Comprehensive Income for the period/year attributable to:**				
	(i) Owners of the Company	(4.45)	(6.52)	(1.71)	(23.35)
	(ii) Non-Controlling Interest	-	0.21	(0.05)	0.07
15	**Total Comprehensive Income for the period/year attributable to:**				
	(i) Owners of the Company	965.36	153.30	162.71	533.04
	(ii) Non-Controlling Interest	(2.49)	5.85	8.49	18.52
16	Paid-up equity share capital	-	-	-	85.07
17	Other Equity	-	-	-	3,517.28
18	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	113.71	19.45	20.33	67.57

HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

Notes:

1 The consolidated financial results of Hester Biosciences Limited (the "Company") and its subsidiaries and its joint venture entity (together referred as the "Group") have been reviewed by the Audit Committee in its meeting held on 29 July 2026 and approved by the Board of Directors of the Company in its meeting held on 30 July 2026.

2 The Statutory Auditors have carried out limited review of these consolidated financial results of the Group for the quarter ended 30 June 2026.

3 Following are the details of consolidated segment wise revenue, results, segment assets and liabilities:

(Amount in INR Million)

Particulars	Quarter Ended			Year Ended
	30 June 2026	**31 March 2026**	**30 June 2025**	**31 March 2026**
	Unaudited	Audited (Refer note 6)	Unaudited	Audited
Segment Revenue				
a. Poultry Healthcare	621.33	647.16	421.22	2,059.71
b. Animal Healthcare	151.11	353.94	419.83	1,266.28
Total Revenue from Operations	**772.44**	**1,001.10**	**841.05**	**3,325.99**
Segment Results				
a. Poultry Healthcare	243.07	231.13	92.29	580.87
b. Animal Healthcare	(41.85)	49.52	132.11	252.70
Total Segment Results	**201.22**	**280.65**	**224.40**	**833.57**
a. Finance cost	30.80	50.95	18.10	109.34
b. Share of Profit in Joint Venture Entity	20.37	18.57	10.49	63.73
c. Other unallocable expenditure (Net)	(826.03)	(2.61)	14.92	29.60
Profit before tax	**1,016.82**	**250.88**	**201.87**	**758.36**
Segment Assets				
a. Poultry Healthcare	1,245.43	1,233.57	2,436.09	1,233.57
b. Animal Healthcare	2,128.68	2,253.88	2,128.70	2,253.88
Unallocated Assets	3,404.63	3,291.96	2,056.94	3,291.96
Total	**6,778.74**	**6,779.41**	**6,621.73**	**6,779.41**
Segment Liabilities				
a. Poultry Healthcare	88.63	158.01	135.09	158.01
b. Animal Healthcare	159.62	233.24	363.16	233.24
Unallocated Liabilities	1,889.85	2,710.27	2,685.72	2,710.27
Total	**2,138.10**	**3,101.52**	**3,183.97**	**3,101.52**

Note: Unallocated assets comprise Property, Plant and Equipment and other assets pertaining to the BSL-3 and Fill Finish facilities capitalised during the previous year. As these facilities are intended to support operations across multiple segments and the associated economic benefits are expected to be derived jointly by both segments, the related assets have not been specifically allocated to any individual segment and are accordingly disclosed as unallocated assets.

4 During the current quarter, Hester Biosciences Africa Limited ("HBAL"), a wholly-owned subsidiary of the Company, entered into a loan amendment agreement with the Gates Foundation (USA), reducing the outstanding principal from USD 12.00 million to USD 5.00 million, waiving all accrued interest, and making the revised loan interest-free.

As the present value of cash flows under the revised terms, discounted at the original effective interest rate, differed from that of the original liability by more than 10%, the modification is considered substantial under Ind AS 109 – Financial Instruments, and has been accounted for as an extinguishment of the original liability and recognition of a new liability at fair value which has resulted in a gain of INR 853.49 million, recognised in the consolidated financial results as exceptional item.

HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

5 During the previous year the Board of Directors of the Company at its meeting dated 11 March 2026 have approved the divestment of 43.81% equity shareholding out of 54.81% in its subsidiary, Texas Lifescience Private Limited ("TLPL") by way of sale/ trasfer of 2,163,377 Equity Shares of INR 10 each at the price of INR 42.34 per share to entity affilaited to existing promoter shareholders of TLPL. TLPL has been ceased to be subsidiary of the company from 27 March 2026 onwards.

6 The figures for quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full year ended 31 March 2026 and the unaudited published year-to-date figures upto 31 December 2025 being the date of the end of the third quarter which were subjected to limited review.

7 Key numbers of the Standalone Financial Results of the Company for the quarter ended 30 June 2026 are as under:

(Amount in INR Million)

Particulars	**Quarter Ended**			**Year Ended**
	30 June 2026	**31 March 2026**	**30 June 2025**	**31 March 2026**
	Unaudited	Audited	Unaudited	Audited
Total income	743.43	978.92	644.36	2,997.71
Profit before tax	197.52	348.70	102.88	696.82
Profit after tax	147.11	263.84	78.38	521.00
Total comprehensive income	147.11	263.34	77.48	520.50

The Standalone Financial Results are available at the Company's website www.hester.in and on the website of the stock exchanges www.bseindia.com and www.nseindia.com.

For and on behalf of the Board of Directors

Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Kadi, Mehsana
Date: 30 July 2026

Chandulal M. Shah & Co.
CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • **(M)** 90330 34430 • **E-mail :** cmshah@cmshah.com • **Website :** www.cmshah.com

Independent Auditor's review report on Quarterly Unaudited Consolidated financial results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Hester Biosciences Limited (the "Holding company") and its subsidiaries and joint venture entity (the Holding, its subsidiaries and joint venture entity together referred to as the "Group") for the quarter ended on June 30, 2026 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a Report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

   We have also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019, issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The statement includes the results of the following subsidiaries and joint venture:

Sr. No.	Name of the Company	Relationship
1	Hester Biosciences Nepal Private Limited	Subsidiary
2	Hester Biosciences Africa Limited	Subsidiary
3	Hester Biosciences Kenya Limited	Subsidiary
4	Hester Biosciences Tanzania Limited	Step-Down Subsidiary
5	Thrishool Exim Limited	Joint Venture Entity

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies has not disclosed the information

CHANDULAL M. SHAH & CO.
AHMEDABAD
CHARTERED ACCOUNTANTS

required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The unaudited consolidated financial results include the interim financial statements of 2 subsidiaries and 1 step-down subsidiary which have been reviewed by other auditors, whose interim financial statements reflect total revenue of INR 66.87 million, total net profit after tax of INR 798.65 million and total comprehensive income of INR 795.44 million for the quarter ended on June 30, 2026, as considered in the consolidated unaudited financial results. The interim financial statements of these subsidiaries have been reviewed by the other auditors whose reports have been furnished to us, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors and the procedures performed by us as stated in paragraph 3 above.

7. The unaudited consolidated financial results include the interim financial statements of 1 subsidiaries which have not been reviewed by their auditors, whose interim financial statements reflect total revenue of INR Nil million, total net (loss) after tax of INR (0.21) million and total comprehensive income of INR (0.72) million for the quarter ended on June 30, 2026, as considered in the consolidated unaudited financial results. The management has certified these financial statements and other financial information.

8. The accompanying Statement includes the group's share of Net Profit after tax of INR 20.37 million for the Quarter ended on June 30, 2026, in respect of 1 joint venture entity. The management has certified these interim financial statements and other financial information of the joint venture entity.

9. Certain of these subsidiaries and joint venture entity are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries ('local GAAP'). The Holding Company's management has converted the financial results of such subsidiaries and joint venture entity from local GAAP to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture entity, is based on the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion on the statement in respect of the matters stated in paragraph 6, 7, 8 and 9 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial statements and financial information certified by the Management.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W

CHANDULAL M SHAH & CO. AHMEDABAD CHARTERED ACCOUNTANTS

I.I. Mans

Irshad I Mansuri
Partner
M. No. 135475
UDIN: 26135475GXAB228184

Place: Ahmedabad
Date: July 30, 2026.

HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

Press Release

30 July 2026

Hester Biosciences Q1 FY27 Results

Standalone: Q1 Revenue up 14%, Profit up 88%
Consolidated: Q1 Revenue down 8%, Profit up 459% *

Hester today announced the unaudited financial results for Q1 FY27

Standalone Financial Highlights

Revenues

(INR Million)

Divisions	Q1			FY26
	FY27	FY26	Change %	
Poultry Healthcare	617.69	416.52	48%	2,060.79
Animal Healthcare	108.44	218.22	-50%	818.32
Total Divisional Product Sales	**726.13**	**634.74**	**14%**	**2,879.11**
Other Operating Income	0.47	0.16	194%	42.25
Revenue from Operations	**726.60**	**634.90**	**14%**	**2,921.36**

Poultry Healthcare Division

1. The Poultry Healthcare Division delivered strong growth during the quarter, with revenues increasing by 48% over the corresponding quarter of the previous year.
2. Growth was driven by higher institutional business, deeper market penetration and continued strengthening of customer engagement across key markets.
3. The division also witnessed encouraging traction in the health products portfolio launched during FY26 which includes feed supplements and disinfectant solutions. These products continue to complement Hester's vaccine business by offering integrated disease prevention and farm health management solutions, while contributing to the division's growth.

Animal Healthcare Division

1. The Animal Healthcare Division continued to be impacted by the timing of government-led immunisation programmes. This primarily reflects delays in tender execution rather than any change in the underlying demand for biologicals for livestock healthcare.
2. Hester remains confident about the long-term growth opportunities in preventive animal healthcare and continues to strengthen its portfolio across commercial and institutional markets.

HESTER

Hester Biosciences Limited
HQ and Registered Office
Village Meda-Adraj
Taluka Kadi
District Mehsana
Gujarat 384441, India
Phone +91 2764 285 502
+91 2764 285 453

Ahmedabad Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 264 45106

Email mail@hester.in
www.hester.in

CIN L99999GJ1987PLC022333

Standalone Profitability Analysis

(INR Million)

Particulars	Q1			FY26
	FY27	FY26	Change %	
Gross Profit Margin	78%	69%	9%	72%
EBITDA	260.34	133.57	95%	871.03
EBITDA%	36%	21%	15%	30%
PAT	147.11	78.38	88%	521.00
PAT%	20%	12%	8%	18%
EPS (in INR, not annualised)	17.29	9.21	88%	61.24

1. Gross profit margins improved to 78% from 69%, supported by favourable product mix and continued operational efficiencies.
2. EBITDA and PAT increased by 95% and 88% respectively, reflecting stronger operating performance and disciplined execution across the business.

Consolidated Financial Highlights

(INR Million)

Particulars	Q1			FY26
	FY27	FY26	Change %	
Revenue from operations	772.44	841.05	-8%	3,325.99
Gross Profit Margin	78%	73%	5%	75%
EBITDA	1,118.06	261.79	327%	1,056.51
EBITDA%	145%	31%	114%	32%
PAT	967.32	172.96	459%	574.84
PAT%	125%	21%	104%	17%

1. * Consolidated profitability during the quarter includes an exceptional gain arising from the amendment of the Gates Foundation loan at Hester Africa. During the quarter, the outstanding loan was reduced from USD 12.0 million to USD 5.0 million, accrued interest was waived and the revised loan was made interest-free, resulting in an exceptional accounting gain of INR 853.49 million.
2. Consolidated revenues were lower compared to the corresponding quarter of the previous year primarily due to lower revenues from the Nepal and Africa operations.
   - Nepal continued to experience variability in institutional order timing and local market conditions.
   - Africa business remained focused on strengthening registrations, expanding market development activities and building long-term commercial opportunities across the continent.

Way Forward

The Company remains committed to its long-term strategy of *Building with Intent. Growing with Science.*

During FY27, Hester will continue to focus on:

1. Strengthening its biologicals portfolio across Poultry and Animal Healthcare.
2. Expanding market penetration across domestic and export markets.

3. Advancing Research and Development through continued investments in new products and regulatory submissions.
4. Improving manufacturing efficiency and enhancing utilisation of recently commissioned facilities.
5. Continuing to strengthen operational excellence, cost discipline and execution capabilities across the organisation.

While certain parts of the business continue to be influenced by the timing of government immunisation programmes and international market conditions, the Company remains focused on building long-term competitive advantages through scientific innovation, manufacturing capability and disciplined execution. Hester believes the investments made over the past few years position the Company well to deliver sustainable growth and create long-term value for all stakeholders.

About Hester Biosciences Limited
Hester Biosciences Limited is one of the India's leading animal health company, manufacturing vaccines and health products since 1997.

Hester has two divisions:
1. Poultry Healthcare division
2. Animal Healthcare division (which includes Ruminants and Pet health segments)

- It is the world's largest manufacturer and supplier of PPR vaccine, having approximately 75% of the world market.
- It has over 70% market share in Goat Pox vaccine in India which is being used to immunise cattle against Lumpy Skin disease.
- It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India.

Hester's vaccine capabilities include multiple platforms such as Chick Embryo Origin, Continuous Cell line, Tissue Culture and Fermentation based live as well as inactivated vaccines.

Hester recognises the vision of ONE HEALTH and works on improving the health of animals by enabling better health for human beings.

For more information, please visit www.hester.in